Trophos

This page shows the latest Trophos news and features for those working in and with pharma, biotech and healthcare.

Biogen buys into Ionis' nusinersen after positive phase III trial

Potential blockbuster spinal muscular atrophy drug will be filed “in the coming months” 

Roche buys rare disease firm Trophos in €470m deal

Roche buys rare disease firm Trophos in 470m deal. Will take control of olesoxime for spinal muscular atrophy. ... Roche is paying 120m upfront for Marseilles-based Trophos, with another 350m promised in the form of milestone payments.
Christine Placet appointed CEO of Trophos

Trophos has promoted its chief financial officer Christine Placet to CEO, replacing Damian Marron. ... Prior to joining Trophos in 2004, Placet served as chief financial officer in several companies across various industries.
Actelion net revenue up 18 per cent for Q2

Actelion also confirmed it has obtained the option to purchase Trophos, a France-based clinical stage pharmaceutical company, for 10m. ... Trophos has a pipeline of new molecular entities in development for the motor neuron diseases amyotrophic lateral
Trophos SA Awarded $1.4mn research grant

Agence Nationale pour la Recherche (ANR), the French research agency, has awarded Trophos SA a $1.4mn research grant to support drug development. ... Biopharmaceutical company Trophos SA is currently heading a project into the efficacy of candidate drug

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Deal Watch table for January 2015

Corporate acquisition. 675. Trophos/Roche. Includes Olesoxime an orphan drug in P2 for spinal muscular atrophy; plus TRO 40303 in P1 for cardiac injury.
Pharma deals during January 2015

A few days later, the acquisition of the French company, Trophos was announced which brings Olesoxime an orphan drug in phase II clinical development for spinal muscular atrophy; plus TRO 40303

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Home based, Editorial Team Leader, Medical Communications: Excellent package

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Senior Medical Writer, Medical Communications: Excellent package

Add my company

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....